ArticlePediatric blood & cancer2017

Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.

Ichiko Kinjyo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.